Printed from Voxsanity (voxsanity.com.au) — NCT07488754 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Brain Cancer
Brain Cancer Trial, Recruiting
NCT07488754
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 80 years old
- People who have been diagnosed with a type of brain tumour called diffuse glioma (a higher-grade type, classified as Grade 3 or Grade 4 by the World Health Organisation), confirmed by laboratory testing of tumour tissue
- People who have already completed standard treatment, which may have included a biopsy or surgery to remove the tumour, followed by radiation therapy and/or chemotherapy
- People whose scans show no signs that the tumour is growing back or that the brain tissue has been damaged by radiation
- People who are functioning reasonably well in daily life, as measured by a standard medical scoring tool called the Karnofsky Performance Scale (a score above 70, meaning the person is able to care for themselves and carry out normal activity with only minor difficulty) (confirm with trial site)
- People who are able to understand the study and agree to take part by giving informed consent
Who may not be able to join:
- People with a lower-grade (slower-growing) type of glioma
- People whose condition shows signs that the tumour is growing back or getting worse — this includes a decline in daily functioning, worsening neurological symptoms, a need to start or significantly increase steroid medication, or scan results showing tumour progression based on established medical criteria
- People who have developed tissue damage in the brain caused by radiation treatment (known as radiation-induced necrosis), unless they have already had surgery to remove that damaged tissue and at least 4 weeks have passed since that surgery, with a follow-up scan completed (confirm with trial site)
- People who need urgent surgery, for example due to a sudden dangerous increase in pressure in the brain
- People who have had serious complications from recent surgery, such as a functioning score below 70 on the Karnofsky scale, a wound infection, or leakage of fluid surrounding the brain and spinal cord
- People where a check of a treatment catheter (a small tube used to deliver medication) shows more than 10% of fluid leaking into the brain's fluid-filled chambers (confirm with trial site)
- People whose surgical cavity (the space left after tumour removal) is open to or connected with the fluid-filled chambers of the brain (confirm with trial site)
- People whose treatment catheter is blocked
- People whose life expectancy is estimated to be less than 3 months
- People who are not able to communicate logically or verbally
- People who are unwilling or unable to cooperate with the study requirements
- People who are unable to give free and informed consent to participate
- People who are currently taking part in another medical research trial
- People who have received another experimental drug within the month before the first dose of this trial's treatment
- People who have previously been treated with the specific investigational substance used in this trial, called [²²⁵Ac]Ac-DOTA-SP
- Women who are pregnant or breastfeeding
- People with serious health conditions affecting other organs that, in the opinion of the treating doctor, would significantly increase the risks of taking part in this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Przemysław Kunert, Professor MD PhD, Medical University of Warsaw
Phone: +48 22 599 2575
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
Medical University of Warsaw
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
1 September 2027
Where this trial is recruiting
🇵🇱 Poland
Primary endpoints
1. Number of patients experiencing clinical progression (as defined below)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.